ONC250117P210000
- 11.50
- 0.000.00%
BeiGene Newsroom
Express News | JPMorgan Chase & Co's Long Position in Beigene Decreases to 9.83% on Jan 3 From 10.33% - HKEX
Beigene Insider Sold Shares Worth $7,370,515, According to a Recent SEC Filing
Indaptus Therapeutics Provides 2025 Outlook, Launching Decoy20 Combination Cohort With BeiGene's Tislelizumab, Expanding Clinical Sites Beyond 8, Updating Higher Dose Cohort, First Patient Dosed In Combination, Focus On Cancer Challenges
BeiGene Issues Overseas Regulatory Announcement on Form 10-K/A Amendment
10-K/A: Annual report (Amendment)
[Brokerage Focus] CMB International stated that the pharmaceutical industry is expected to outperform the market in 2025, benefiting from overseas interest rate cuts and improvements in the domestic macro environment.
Jinwu Finance News | Zh Xia International released a Research Report stating that on January 3, the General Office of the State Council issued the "Opinions on Deepening the Reform of Pharmaceutical and Medical Instruments Regulation to Promote High-Quality Development of the Pharmaceutical Industry." The policy mentions deepening the reform of the entire process of pharmaceutical and medical instruments regulation, accelerating the establishment of a unified national market in the field of pharmaceutical and medical instruments, creating an innovative ecosystem with Global competitiveness, and promoting the transition of China from a major pharmaceutical country to a strong pharmaceutical country. The policy aims for significant improvements in the quality and efficiency of the review and approval of Innovative Drugs and medical instruments by 2027, establishing a regulatory system that aligns with pharmaceutical innovation and industrial development. By 2035, the pharmaceutical industry will have...
BEIGENE issued 0.5429 million ordinary shares due to the exercise of stock options.
BEIGENE (06160) announced that the company will issue 0.5429 million ordinary shares due to a Director exercising stock options on January 8, 2025.
BEIGENE (06160.HK) issued 0.5429 million shares due to the Director exercising stock options.
Gelonghui reported on January 8 that BEIGENE (06160.HK) announced the issuance of 0.5429 million shares of common stock due to a Director exercising stock options on January 8, 2025.
MAIA Biotechnology Shares Rise After Supply Agreement With BeiGene
Express News | Maia Biotechnology Announces Clinical Supply Agreement With Beigene for Upcoming Phase 2 Trials in Three Cancer Indications
BEIGENE grants stock options and restricted share units.
BEIGENE (06160) announced that on December 31, 2024, the Board of Directors' Compensation Committee granted an option to one grantee to subscribe for a total of 2,271 American depositary shares and granted restricted stock units involving a total of 35,469 American depositary shares to 108 grantees, in accordance with the terms of the 2016 Options and Incentive Plan.
Ensem Therapeutics Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
BeiGene Announces Share Options and RSUs Grant to Employees
Beigene (06160) has granted stock options and restricted stock units.
BEIGENE (06160) announced that on December 31, 2024, the Board of Directors' Compensation Committee based on 20...
Express News | Beigene Announces Appointment of Giancarlo Benelli as Head of Europe
BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe
Nona Biosciences Announces Update on Its Collaborator DualityBio's Antibody-Drug Conjugate (ADC) Collaboration With BeiGene
News On BeiGene Ltd. (BGNE) Now Under ONC
BEIGENE has issued approximately 0.2565 million shares due to the return of restricted stock units.
BEIGENE (06160) announced that on December 31, 2024, approximately 0.2231 million shares will be issued due to the vesting of restricted stock units granted under the equity plan (excluding company Directors), and approximately 0.0334 million shares will be issued due to the vesting of restricted stock units granted to company Directors under the equity plan. A total of approximately 0.394 million shares will be issued from exercising stock options between December 1, 2024, and December 31, 2024.
Duality Biologics Announces B7H4 ADC Milestone Achievement and License Exercise by BeiGene